Professor Dominic Man-Kit Lam | Co-Founder and Chairman
Professor Lam completed his BSc in Mathematics (Lakehead University, 1967), MSc in Physics (University of British Columbia, 1968) and PhD in Medical Biophysics (University of Toronto, 1970), DSc (Hon., Lakehead University, 2015). In 1970, Lam was awarded a Centennial Award from Canada to study at Harvard Medical School under Nobelists, Torsten Wiesel and David Hubel (who received the 1981 Nobel Prize in Physiology or Medicine, for their discoveries on information processing and development of the eye and the brain). He made major breakthroughs in vision research and was invited to teach at Harvard in 1972. In 1977, he became Professor of Ophthalmology at Baylor College of Medicine in Houston, Texas. Lam has published over 100 scientific articles, including more than 10 in Nature and PNAS, as well as more than 20 scientific and artistic books.
Professor Lam is a world acclaimed artist, scientist, philanthropist, educator, medical professor and entrepreneur.
In 1983, Professor Lam founded the Center for Biotechnology, and helped to establish the Woodlands Research Forest in Houston. In 1985, he invented an ophthalmic drug and started the first biotech company in Texas, which went public in 1988, raising USD 33 million and was recognized as Father of Texas Biotechnology. He has received many honors and awards for these accomplishments, including the Medal of merit from the President George H.W. Bush, High Tech Entrepreneur of the Year (1989) and Asia Society Man of the Years. In 1988, Professor Lam was invited by Nobel Laureates Professors Yang Chen Ning and Charles Kao to found and direct the Hong Kong Institute of Biotechnology (HKIB), with a HKD170,000,000 grant from the Hong Kong Jockey Club. He was also recognized as the Father of Hong Kong Biotechnology. HKIB inspired the establishment of to-day’s HK Science and Technology Park at the same location in the 90s.
Since the 1970’s Professor Lam has been committed to charity and philanthropy and began by donating sales and auctions of his own paintings to support the Retina Research Foundation in America. He established the World Eye Organization (WEO) in 1999, offering free services for the prevention and treatment of visual disorders in China. The WEO is a charitable organization dedicated to the prevention and treatment of eye diseases. To date, the WEO has 9 charitable eye centers and provides eye-care and education to many rural areas in China, and plans to start such services in other parts of the world.
Professor Lam’s frequent visits to China for charities and lectures since 1980s also made him aware of the seriousness of infectious diseases and the urgent need to eradicate or control them. Even though injectable vaccines were available, the compliance was often low because of high costs and inconveniences. Such concerns inspired Lam and his colleagues to develop “Edible or Oral Vaccines” in the early 90s, initially against Hepatitis B. This invention was selected as one of 10 most important inventions for the 21st century by Time Magazine and one of 5 patents that will transform business and technology by MIT.
More recently, in view of major technological advances in Artificial Intelligence, Robotics, etc., as well as the escalation of the number of the sight-impaired globally, Professor Lam has set his sight on developing devices such as robots, intelligent glasses, and more to help the blind and sight-impaired in improving their activities, as well as to prevent sight deterioration. These are the major focuses of Second Sight and iVision.
Taken together, Second Sight Technology Corporation is honored to have Professor Dominic Lam as Co-Founder and Chairman of the Board of Directors.
Jack W. Chung, Esq. | Co-founder, Inventor and CEO
Jack W. Chung, Esq. is an attorney at law, with a practice focused on international commercial litigation, and technology transfer‐related business transactions between the United States and China. Mr. Chung’s concentration is in dealing with disputed matters in business relating to intellectual property issues. He has represented clients in licensing agreements, patent‐related matters, settlement agreements, enforcement of trademark rights, and other business transaction matters. He is the inventor of a navigation system for the visually impaired. He founded iVision Technology Corporation in 2017 and Second Sight Technology Corporation in 2018. Mr. Chung was an adjunct professor at the City University School of Law teaching intellectual property law and Internet and the Law in 2012-2013. He established his own firm, Law Offices of Jack W. Chung, P.C., in 2004. He is also currently Of Counsel to the Law Offices of Albert Wai‐Kit Chan, PLLC. Earlier in his career, Mr. Chung was active in the Chinese‐American community. He was a director of the United States‐China Lawyers Society (USCLS) and a business advisor certified by the New York State Small Business Development Center program; in this capacity, he advised more than 300 small business clients. He also has been a Director at the United States-China Intellectual Property Institute since 2015. Mr. Chung was the Media Chair of Supreme Court Justice Doris Ling‐Cohan’s campaign in 2002, as well as various other election campaigns in New York City. He graduated from Brooklyn College, cum laude, and received his J.D. from CUNY School of Law. He is admitted to practice in the State of New York and the Supreme Court of the United States. Mr. Chung is fluent in English and two Chinese dialects: Cantonese and Mandarin.
Dr. Keith Chan | Senior Scientific Advisor
Dr. Chan assists iVision/Second Sight with strategizing our company’s technologies and patent portfolio. Dr. Chan is currently Senior Advisor for the Cornerstone Intellectual Property Foundation in Taiwan and adjunct professor at the Graduate Institute of Intellectual Property, College of Commerce, National Chengchi University and adjunct professor and advisor at the Research Center for Drug Discovery, National Yang Ming University in Taipei, Taiwan. He is also serving as Director of International Affairs, GloboAsia LLC, Rockville, Maryland. Dr. Chan co-founded GloboMax LLC, a drug development organization, in Hanover, Maryland, in July 1997, and served as consultant for numerous multi-national pharmaceutical biotech firms in the U.S, Europe and Asia. GloboMax LLC was acquired by ICON, plc. in August 2003, and Dr. Chan exited the operation. Prior to that, he joined the U.S. FDA in 1995 as Director of Division of Bioequivalence, Office of Generic Drugs, responsible for the policy making and approving the generic drugs and managing the pioneer drugs challenges. In addition, he has served as adjunct Professor at the School of Pharmacy, University of Maryland at Baltimore for many years and also as Adjunct Professor and National Board of Advisor, College of Pharmacy, University of Minnesota since 1984. Before that, Dr. Chan worked for Ciba-Geigy Corporation in Ardsley, New York, for 15 years, and held various senior and management positions. His experience is very diverse including managing and executing preclinical animal studies, bioassay development, Phases I to VI Pharmacokinetics, pharmacodynamics, bioavailability, bioequivalence studies, outside contract, regulatory submission, advanced drug delivery systems in vivo evaluation, and all phases of generic and new drug development. He has published more than 150 abstracts and research articles in peer-reviewed journals and over 200 professional presentations. He was elected as Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 1995 for his scientific accomplishments on drug absorption in humans. Although much of his career has been based in the United States, Dr. Chan has also assisted Asian pharmaceutical and biotech companies over the last 14 years. He has organized numerous workshops and conferences in China, Taiwan, Hong Kong, Singapore and Korea. He lectures frequently in Asia and serves as a scientific advisor for many regulatory agencies in Asia. Over the last several years, he has successfully assisted many Asian companies in their technology transfers and licensing deals to and from the U.S., as well as with numerous regulatory submissions to the U.S. FDA. Dr. Chan obtained his Ph.D. degree in Pharmaceutics from the University of Minnesota in January 1980.
Jamy Tsang | Vice President
Mr. Tsang has more than 15 years of experience in marketing and sales in the automobile industry and is Sales Director. As Sales Director, he determined annual unit and gross-profit plans by implementing marketing strategies; analyzing trends and results. He maintained sales volume, product mix, and selling price by keeping current with supply and demand, changing trends, economic indicators, and competitors. He also managed sales staff recruiting, selecting, orienting, and training, as well as monitored staff job results by counseling and disciplining employees; planning, monitoring, and appraising job results. Mr. Tsang has conducted business transactions between the US and Hong Kong. He is experienced in negotiation and strategic business planning. He utilizes his years of experience in sales to meet sales goals, build relationships, coaching and manage staff, manage processes, develop market knowledge, and develop budgets.
Jennifer P.T. Lau | Director for Business Strategy (China and Asia Pacific)
Jennifer P.T. Lau has over 20 years of experience in investment banking, market, project management, wealth management, and financial consulting. With globally wide ranging contacts, she has been able to develop and maintain over 20 years of hard working and successful projects. Ms. Lau has a proven record of successful fund raising projects, investment, collaborated in many projects (worth US$ 10 mil.) and IPO Listing. She is currently a vice president at an investment fund and Director of Business Development at public company. Past work included management of in-house discretionary accounts; marketing regional equities of Hong Kong, China, Korea, Singapore, and Malaysia; and servicing institutional clients covering the region and in Europe. Ms. Lau is a graduate of University of Kensington, UK with a Bachelor degree in Business Management (with studies in stock market and finance) and a diploma of English law. She is fluent in English, Mandarin, Cantonese and Shanghainese.